China, Xinjiang COVID-19 Cases Continue
Source of Infection Unclear, Nucleic Acid Testing for Urumqi Residents
Chinese Researchers Report Antibody Formation in Phase 2 Clinical Trial of COVID-19 Vaccine
[Asia Economy Beijing=Special Correspondent Jo Young-shin] The novel coronavirus infection (COVID-19) continues to persist in Xinjiang Autonomous Region in western China, with 7 confirmed cases reported.
As the source of infection remains unidentified, Chinese health authorities have decided to conduct free COVID-19 testing in Urumqi, the capital of Xinjiang.
The National Health Commission of China announced that as of midnight on the 21st, the cumulative number of confirmed COVID-19 cases across 31 provinces in China reached 83,693, with 4,634 deaths. On the 20th alone, 11 new confirmed cases were reported, 7 of which were from Xinjiang Autonomous Region. Three cases were imported from overseas, and one case was from the Xinjiang Production and Construction Corps (a paramilitary organization).
Since the first patient was reported on the 16th, a total of 54 people in Xinjiang have been confirmed positive.
The state-run Global Times reported on the same day that Chinese health authorities are conducting large-scale free nucleic acid testing for local residents in Urumqi, the capital of Xinjiang. Urumqi has a population of 3.5 million.
Urumqi health authorities are currently investigating the source of infection by categorizing cases into symptomatic, suspected, and asymptomatic.
The newspaper reported that about 1,600 medical personnel are participating in the COVID-19 testing.
The number of confirmed COVID-19 cases in the Greater China region is 1,958 in Hong Kong, 46 in Macau, and 455 in Taiwan, totaling 2,459 cases.
The Global Times also reported that Chinese researchers have succeeded in antibody formation in the phase 2 clinical trial of a COVID-19 vaccine on the same day.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
According to the Global Times, Chinese researchers administered the COVID-19 vaccine to 508 adult subjects aged 18 to 83, and most of the subjects developed neutralizing antibody immune responses. The phase 2 results were published in the medical journal Lancet.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
